Didn't find the company you were looking for? Our full system contains all Danish companies, including comprehensive credit risk reports. Register here to get started.
You can find text and video tutorials here that explain how to use our system.
Ascendis Pharma Growth Disorders A/S
CVR number: 32323677
Tuborg Boulevard 12, 2900 Hellerup
Income statement (kEUR)
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -14 434.89 | -17 880.18 | -30 184.95 | -47 933.48 | -57 035.67 |
| Costs of management | - 108.65 | - 117.16 | - 116.20 | - 116.47 | - 116.46 |
| EBIT | -14 543.54 | -17 997.34 | -30 301.15 | -48 049.95 | -57 152.13 |
| Other financial income | 0.08 | 0.31 | |||
| Other financial expenses | - 796.12 | -1 281.93 | -1 858.50 | -3 026.02 | -4 305.04 |
| Pre-tax profit | -15 339.66 | -19 279.19 | -32 159.65 | -51 075.97 | -61 456.86 |
| Income taxes | 253.31 | 61.08 | 118.09 | 75.69 | |
| Net earnings | -15 339.66 | -19 025.88 | -32 098.57 | -50 957.88 | -61 381.17 |
Assets (kEUR)
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Intangible rights | 163.64 | 109.09 | 54.55 | ||
| Intangible assets total | 163.64 | 109.09 | 54.55 | ||
| Tangible assets total | |||||
| Participating interests | 6 529.10 | 6 529.10 | 8 439.09 | 8 439.09 | |
| Investments total | 6 529.10 | 6 529.10 | 8 439.09 | 8 439.09 | |
| Non-current loans receivable | 6 529.10 | ||||
| Long term receivables total | 6 529.10 | ||||
| Inventories total | |||||
| Current trade debtors | 53.01 | 39.61 | |||
| Prepayments and accrued income | 964.99 | 637.80 | 205.44 | ||
| Current other receivables | 1 579.25 | 1 491.15 | 2 036.20 | 1 043.40 | 5 129.23 |
| Short term receivables total | 2 544.24 | 2 128.95 | 2 241.64 | 1 096.40 | 5 168.84 |
| Cash and bank deposits | 903.75 | 0.34 | 1 905.39 | 10.51 | 7.45 |
| Cash and cash equivalents | 903.75 | 0.34 | 1 905.39 | 10.51 | 7.45 |
| Balance sheet total (assets) | 10 140.72 | 8 767.47 | 10 730.68 | 9 546.00 | 13 615.38 |
Equity and liabilities (kEUR)
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Share capital | 67.02 | 67.02 | 67.02 | 67.02 | 67.02 |
| Other reserves | -50.27 | -50.27 | -50.27 | -50.27 | -50.27 |
| Retained earnings | -23 036.55 | -38 376.21 | -57 402.09 | -89 500.66 | - 140 458.54 |
| Profit of the financial year | -15 339.66 | -19 025.88 | -32 098.57 | -50 957.88 | -61 381.17 |
| Shareholders equity total | -38 359.46 | -57 385.34 | -89 483.90 | - 140 441.79 | - 201 822.96 |
| Non-current owed to group member | 45 302.04 | 65 210.72 | 97 208.89 | 149 981.91 | 215 432.42 |
| Non-current liabilities total | 45 302.04 | 65 210.72 | 97 208.89 | 149 981.91 | 215 432.42 |
| Other non-interest bearing current liabilities | 1 052.86 | 942.09 | 3 005.69 | 5.88 | 5.92 |
| Accruals and deferred income | 2 145.27 | ||||
| Current liabilities total | 3 198.13 | 942.09 | 3 005.69 | 5.88 | 5.92 |
| Balance sheet total (liabilities) | 10 140.72 | 8 767.47 | 10 730.68 | 9 546.00 | 13 615.38 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
... and more!
No registration needed.